The preliminary research study design was a randomized, double-blinded, placebo-controlled, remote study on the MasterMind™ product. With a sample of 50 individuals, the inclusion criteria was applied to healthy individuals, with no history of mental illness or depression, and had to be between the ages of 18 and 65 years of age. Participants were given either a formulated dose of MasterMind nootropic or a placebo.
Subjects completed a series of computerized cognitive function assessments at baseline and at week 4, using Neurotrax and Neurotrax Israel, Ltd., to measure global cognitive score, memory scores, executive function, attention, and processing speed. Daily use of a cognitive mobile app was recorded with the consumption of the study product and the completion of a daily subjective questionnaire, using eBrain, to measure participant protocol compliance.
Endpoints used were the self-reported questionnaire scores, changes in computerized cognitive function assessment scores, and changes in POMS standardized questionnaires scores.